REVIEW

CAR-T cells: Early successes in blood cancer and challenges in solid tumors

Hassan Dana a,†, Ghanbar Mahmoodi Chalbatani b, c, †, Seyed Amir Jalali c, Hamid Reza Mirzaei b, Stephan A. Grupp d, *, Eloah Rabello Suarez e, Catarina Raposo f, Thomas J. Webster g

a Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran 13145-158, Iran
b Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613151, Iran
c Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717434, Iran
d Division of Oncology, Department of Pediatrics, the Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
e Center for Natural and Human Sciences, Federal University of ABC, Santo Andre’, SP 09210-580, Brazil
f Department of Pharmaceutical Sciences, State University of Campinas (UNICAMP), Campinas, SP 13083-871, Brazil
g Faculty of Pharmaceutical Sciences, State University of Campinas (UNICAMP), Campinas, SP 13083-871, Brazil

Received 4 May 2020; received in revised form 20 July 2020; accepted 21 August 2020

KEY WORDS
Immunotherapy; T cell therapy; Chimeric antigen receptor (CAR); Genetic engineering

Abstract New approaches to cancer immunotherapy have been developed, showing the ability to harness the immune system to treat and eliminate cancer. For many solid tumors, therapy with checkpoint inhibitors has shown promise. For hematologic malignancies, adoptive and engineered cell therapies are being widely developed, using cells such as T lymphocytes, as well as natural killer (NK) cells, dendritic cells, and potentially others. Among these adoptive cell therapies, the most active and advanced therapy involves chimeric antigen receptor (CAR)-T cells, which are T cells in which a chimeric antigen receptor is used to redirect specificity and allow T cell recognition, activation and killing of cancers, such as leukemia and lymphoma. Two autologous CAR-T products have been approved by several health authorities, starting with the U.S. Food and Drug Administration (FDA) in 2017. These products have shown powerful, inducing, long-lasting effects against B cell cancers in many cases. In distinction to the results seen in hematologic malignancies, the field of using CAR-T products against solid tumors is in its infancy. Targeting solid tumors and trafficking CAR-T cells into an immunosuppressive microenvironment are both
1. Introduction

Examples of anti-cancer immunosurveillance, the existence of natural T cells with anti-cancer properties, and the ability to genetically engineer cells to target and destroy cancer cells, have taught us that the immune system plays a major therapeutic role in fighting cancer. For decades, there have been four pillars of anti-cancer therapy: surgery, radiation, chemotherapy and immunotherapy, with some of these active in cancers that have spread beyond the primary site. We can add to this armamentarium targeted small molecule inhibitors, which have been very effective in specific cancers such as chronic myelogenous leukaemia, but this still leaves the field with large areas of unmet medical need. Over the last decade, we have seen significant examples of successful therapy with genetic reprogrammed autologous T cells which utilize a chimeric antigen receptor (CAR)-T cells, with high remission rates and sustained remissions in B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The autologous products use a complex process that requires collection from each individual patient and “bespoke” manufacturing with full release testing for each individual patient product. The CAR-T approach recognizes antibody-type epitopes on the surface of the cells in an HLA-independent manner. The CAR-T fusion molecule provides antigen recognition and binding (such as the B cell target CD19), coupled with precisely defined T cell activation and co-stimulatory domains. The results with CAR-T cells have allowed us the hope that we have added a fifth major pillar to anti-cancer therapies.

2. Milestones leading to the CAR-T cell concept

Immunotherapy comes in many forms. By far the most traditional forms of immunotherapy are monoclonal antibodies (native or conjugated) and allogeneic stem cell transplantation. Other approaches, at various stages of development, include cancer vaccines, exosomes, cytokine therapy (such as INF-γ, IL-2, IL-15, IL-27, etc.), pulsed or genetically modified dendritic cells (DC), natural killer (NK) cells, tumor-infiltrating lymphocytes, cytokine-induced killer cells, and CAR T cells. NK cells utilize KIR receptors. DCs can be isolated, differentiated, and propagated ex vivo, although increasing DC numbers ex vivo to clinically useful doses is more of a challenge. DCs can be pulsed with an antigen as a vaccination approach, and can undergo genetic manipulation, which then can allow them to enhance immune activation against tumor antigens. Genetically modified DCs function for the recognition and subsequent immune reaction for the immunological cancer response through signaling via B cells and especially T cells, leading to their activation and greatly enhanced function. The complex formation of modified DCs with T cells relay information involving the antigen response, which can be altered in the self and non-self-recognition process through co-stimulatory molecules as well as peptide antigens on the DCs.

More recently, CAR-T therapy has indeed initiated a new era for cancer treatment. It made gratifying achievements in treating hematologic malignancies like lymphoma and leukaemia, with new data being published in solid tumors such as glioblastomas and neuroblastoma. Chimeric antigen receptors have been also introduced in NK as another form of cellular immunotherapy, which can also cause cytotoxicity to cancer cells. Despite some advantages, such as the recognition of tumor cells in both CAR-dependent and CAR-independent manners, with no clonal expansion and no immune rejection, the isolation, purification, and transduction of primary NK cells are complicated and usually produce a heterogeneous population with reduced expansion. As an alternative to the use of primary NKS, it is common the use of an irradiated established tumor cell line (NK-92), which must be injected in the patients. This further highlights the new platform CAR-T cell therapy has provided.

The concept of CAR-T therapy was developed to overcome significant barriers in cancer immunotherapy related to T cell recognition of cancer antigens. CAR-T cells recognize cell surface antigens and are not compromised by tumor variants with low or absent surface expression of major histocompatibility complex (MHC) antigens, which would otherwise preclude T cell recognition of tumor antigens. They are not MHC-restricted, thus, simplifying the construction of these therapeutic cells. The interaction with the tumor-associated antigens (TAAs) is driven by a single chain or similar binding domains. It means that the construction of CAR-T cells with the desired specificity is possible with recognition of any surface structure to which there is an available monoclonal antibody. Another critical advance leading to the first responses in CAR-T clinical trials was the incorporation of co-stimulatory domains like 4-1BB and CD28 into CAR designs, which has dramatically enhanced the potency of CAR-T cell responses. Alternatively, if recognition of intracellular epitopes is desired, which is a significant fraction of potential TAAs such as cancer testis antigens, this requires engineered T cell receptors (TCRs) and MHC matching with the patient.

2.1. CAR-T cells in the treatment of hematological tumors

As indicated above, the most significant clinical results have come from trials studying second-generation autologous CD19-specific CAR-T cell therapies, starting with remarkable initial clinical results in recurrent chronic lymphocytic leukemia (CLL). Subsequent reports have shown encouraging results using CD19 CAR-T cells in acute lymphoblastic leukemia.
leukemia (ALL)\textsuperscript{22} and diffuse large B-cell lymphoma (DLBCL)\textsuperscript{23}. CD19 directed CAR-T cell therapy has demonstrated the power of receptor engineering while offering long-term disease control in many cases of hematopoietic cancers\textsuperscript{24} (Table 1\textsuperscript{25}). The long term survivors after anti-CD19 CAR-T also included allogeneic hematopoietic stem cell transplants (allo-HSCT). The vast majority of ALL patients on the ELIANA registration trial for the CD19 CAR-T product CTL019 (tisagenlecleucel) did not go on to allo-HSCT\textsuperscript{41}. Despite being potentially curative, allo-HSCT can lead to fatal complications at rates greater than that seen with CAR-T, including treatment-related mortality and graft vs. host diseases.

Unfortunately, resistance to Anti-CD19 CAR-T therapy is a reality, and bispecific CAR-T cells, like anti-CD19/CD22 and anti-CD19/CD20 are promising options that are currently in clinical trials (NCT03448393 and NCT03271515, respectively).

2.2. CAR-T cells in the treatment of solid tumors

Clinically, the implementation of CAR-T therapy in solid tumors is still at the very earliest stages. In addition to the issues listed above, the tumor microenvironment adapts to limit T cell trafficking and function, using mechanisms such as: (a) hypoxia, nutritional depletion, oxidative stress\textsuperscript{42}; (b) the presence of soluble suppressive factors, cytokines, and suppressive immune cells such as myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophage (TAM)/tumor-associated neutrophils (TAN)\textsuperscript{43}; (c) prevention of trafficking and the penetration of T cells into a solid tumor mass (physical barriers)\textsuperscript{44}; and (d) the presence of negative regulators of T cell function (for example, upregulation of cytoplasmic and surface inhibitory receptors such as programmed death 1 (PD-1) and T lymphocyte-associated antigen 4 (CTLA-4)\textsuperscript{45}). To overcome these limitations, advancements in cell engineering, such as armored CAR-T cells (Fig. 1), and further investigations into tumor immunology are being undertaken.

In a clinical trial, where neuroblastoma patients were treated with GD2 ganglioside specific CAR-CTLs, four of the eight patients with an evaluable disease had evidence of tumor necrosis or regressions, including one sustained CR. None developed detectable antibodies to CAR-CTLs, and there were no adverse events attributable to the genetically modified T cells in the 11 subjects followed for up to 24 months\textsuperscript{46,47}. In another interesting study, Brown et al.\textsuperscript{48} demonstrated the clinical response of a patient with recurrent multifocal glioblastoma who received multiple infusions of anti-IL-13Ra2 CAR-T cells over 220 days through two intracranial delivery routes (infusions into the resected tumor cavity followed by infusions into the ventricular system). Their data showed that intracranial infusions of anti-IL-13Ra2 CAR-T cells were not associated with any high-grade toxic effects (\textgtr\textless grade 3). After CAR-T cell therapy,
| CD19-positive B-cell malignancy | n | LD chemotherapy | Adverse effect | Long-term EFS | PFS | CAR-T cell dose/kg | OS | Outcome | Best response duration | Ref. |
|-------------------------------|---|-----------------|----------------|---------------|-----|-------------------|----|---------|------------------------|-----|
| FL                            | 2 | FLU (post T-cell infusion) | Lymphopenia | ND | ND | 100–200 \( \times 10^7/m^2 \) total T cells | ND | No responses | ND | 25 |
| CLL, ALL, NHL, CLL, SMZL       | 9 | None or (CTX) | B cell aplasia, fever, hypotension, death | ND | ND | 0.4–3 \( \times 10^7 \) | 6 PR, 1 CR, 1 NE | CR up to 12 week | CR > 18 months | 26 |
|                               | 8 | CTX, FLU | B cell aplasia, CRS | ND | ND | 0.3–3 \( \times 10^7 \) | 6 PR, 1 CR, 1 NE | CR up to 12 week | CR > 18 months | 27 |
| CLL                           | 14 | CTX, FLU | B cell aplasia, CRS, TLS, neutropenia | ND | 18-month PFS: 28.6% | 1.4–113 \( \times 10^7 \) | 29 months; 18-month, OS 71% | CR, 4 PR | CR up to 53 months | 28, 29 |
| ALL                           | 16 | CTX | Severe CRS | ND | ND | 0.14–0.3 \( \times 10^7 \) | 14 CR, 12 MRD | CR up to 3 months | 30, 31 |

The peak value of CTL019 was statistically associated with response \((P = 0.008)\), higher peak expansion of CTL019 associated with CRS, and CRS was associated with clinical response \((P < 0.05)\).

The threshold where patients are at high risk for clinical complications secondary to sCRS. *\( P < 0.05 \), unpaired \( t \) tests at the corresponding time point. Specific \( P \) values for the time points are as follows: Day 2, \( P = 0.035 \) \((n = 13)\); Day 4, \( P = 0.025 \)
| Group | Match | Allo-HSCT preparative regimen, DLI; none | B cell aplasia, CRS, hypotension, TLS | Other effects | 6-month overall survival was 78% | 6-month overall survival was 78% |
|-------|-------|----------------------------------------|----------------------------------------|---------------|----------------------------------|----------------------------------|
| CLL, NHL | 20 | Allo-HSCT preparative regimen, DLI; none | B cell aplasia, CRS, hypotension, TLS | Other effects | 0.04–0.8 × 10^7 | 2 PR, 6 CR, 8 SD, 4 PD |
| ALL | 30 | None or VP/CTX | CRS, CNS toxicity | Other effects | 0.2–1.2 × 10^7 | 27 CR, 22 MRD |
| ALL, CLL | 8 | Allo-HSCT preparative regimen; none immediately before T-cell | None | Other effects | 1.9–11 × 10^7 | 1 CR, 1 PR, 1 SD, 2 cCR, 3 NR |

(continued on next page)
Table 1 (continued)

| CD19-positive B-cell malignancy | n | LD chemotherapy | Adverse effect | Long-term EFS | PFS | CAR-T cell dose/kg | OS | Outcome | Best response duration | Ref. |
|---------------------------------|---|-----------------|----------------|---------------|-----|-------------------|----|---------|------------------------|-----|
| DLBCL, PMBCL, follicular        | 22 | CTX, FLU        | Neurologic toxicities, myelodysplastic syndrome, vision loss | ND | 12-month PFS 63.3% | 0.1–0.6 × 10^7 | ND | 4 PR, 12 CR, 4 PD, 2 SD | CR > 24 months | 36 |
| ALL, NHL                        | 21 | CTX, FLU        | CRS, B cell aplasia | 78.8% at 4.8 months | ND | 0.3–0.003 × 10^7, 2 × 10^5 | 51.6% at 9.7 months | ND | 14 CR, 13 MRD | CR up 19 months | 37 |
| NHL                             | 32 | CTX, FLU        | Severe neurotoxicity, CRS | ND | ND | 2 × 10^5, 2 × 10^6, 2 × 10^7 EGFRt+ cells/kg | 10 CR, 19 ORR of 30 evaluable | ND | 38 |
| ALL                             | 45 | CTX, FLU        | Severe neurotoxicity, CRS | 50.8% at 12 months | ND | 0.5 × 10^6, 1 × 10^6, 5 × 10^6, 10 × 10^6, 10^7 EGFRt+ cells/kg | 69.5% at 12 months | MRD-negative CR 93% | 27 months | 39 |

There was an association between the percentage of central memory T cells among the infused CAR-T cells and peak blood CAR T-cell levels ($P < 0.001$; Spearman $r = 0.7$). The concentrations of CSF CD19-CAR T cells were higher in patients who developed neurotoxicity than in those who did not ($P = 0.0039$). There was no effect of dose level ($P = 0.32$), disease burden ($P = 0.93$), CD19 antigen load ($P = 0.23$), or fludarabine and cyclophosphamide lymphodepletion ($P = 0.32$) on the occurrence of severe neurotoxicity; however, the presence of severe...
regression of all intracranial and spinal tumors, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid, was observed. This clinical response was continued for 7.5 months after the initiation of CAR-T cell therapy\(^48\). These results further proved that CAR-T cells could drive clinical responses in advanced cancer patients. Looking more broadly, several clinical trials have been conducted or are ongoing, as shown in Table 2.

In contrast to hematological malignancies, solid tumors not only lack conventional co-stimulatory molecules, which may be expressed on malignant and normal B lymphocytes but also have evolved mechanisms to suppress the immune system actively\(^49\)\(^\text{-}\)\(^51\). Tumor cells produce several immunosuppressive molecules and/or recruit multiple immunosuppressive cells to evade or misdirect a tumor-specific immune response\(^52\)\(^\text{-}\)\(^53\). The prostaglandin 2 (PGE2)/EP2/protein kinase A (PKA) signaling pathway combined with adenosine mediates immunosuppression, activates PKA, and blocks TCR activation. A small peptide called the “regulatory subunit I anchoring disruptor” (RIAD) diminishes the negative effects of PKA on TCR activation—a function that investigators employed to improve T cell function. By the generation of CAR-T cells expressing RIAD, Newick et al.\(^54\) showed that blocking the upstream immunosuppressive mediators of PKA activation, such as PGE2 and adenosine, could improve TCR signaling, increase cytokine release, and increase CAR-T cell infiltration, leading to greater tumor cell killing. Chronic inflammation activity is a hallmark of the tumor microenvironment and generates higher levels of reactive oxygen species (ROS) that can abrogate anti-tumor activity. Ligtenberg et al.\(^55\) proposed that CAR-T cells overexpressing catalase (CAT) would perform better compared to conventional CAR-T cells. Their data indicate that CAT—CAR-T cells produce more intracellular CAT, resulting in a reduced oxidative state with less ROS accumulation in both the basal and activated states. The CAT—CAR-T cells maintained an anti-tumor activity even within a H2O2 hostile environment\(^55\)\(^\text{-}\)\(^56\). T cell exhaustion is often found in solid tumors, where the immune checkpoint molecules are usually overexpressed, e.g., programmed cell death ligand 1 (PD-L1). The release of immune checkpoint blockade antibodies by armored CAR-T cells into the tumor microenvironment is another important effort to improve CAR-T function. Anti-PD-L1 releasing CAR-T cells, for example, were able to decrease tumor growth in five times when compared with the CAR-T cells alone in a humanized mice model of renal cell carcinoma, with remarkable immune checkpoint blockade\(^57\). Some anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies-expressing CAR-T cells and PD-1 knockout-engineered CAR-T cells for different targets are currently under clinical trials. Altogether, it seems that modification of CAR-T cells by different means (e.g., gene-editing tools, pharmacological inhibitors, and others) will likely be the best way to open new avenues to achieve results in solid tumors similar to those seen in hematologic malignancies\(^58\)\(^\text{-}\)\(^60\).

3. Limitations of CAR-T therapy and counteracting strategies

3.1. On-target/off-tumor toxicity

Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self-

| CAR-T cells in blood cancer and solid tumors | 1135 |
|---|---|
| **Table 2** | **On-target/off-tumor toxicity** |
| **DIBCL** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **CRS** | **CAR-T cells in blood cancer and solid tumors** |
| **Intracranial** | **1135** |
| **Spinal** | **On-target/off-tumor toxicity** |
| **Tumors** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Regression** | **CAR-T cells in blood cancer and solid tumors** |
| **Cytokines** | **On-target/off-tumor toxicity** |
| **Immune Cells** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Cerebrospinal Fluid** | **CAR-T cells in blood cancer and solid tumors** |
| **Clinical Response** | **On-target/off-tumor toxicity** |
| **7.5 Months** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Initiation of CAR-T Cell Therapy** | **CAR-T cells in blood cancer and solid tumors** |
| **Clinical Trials** | **On-target/off-tumor toxicity** |
| **Advanced Cancer Patients** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Solid Tumors** | **CAR-T cells in blood cancer and solid tumors** |
| **Co-stimulatory Molecules** | **On-target/off-tumor toxicity** |
| **Malignant and Normal B Lymphocytes** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Evolved Mechanisms** | **CAR-T cells in blood cancer and solid tumors** |
| **Immunosuppressive Molecules** | **On-target/off-tumor toxicity** |
| **Recruit Multiple Immunosuppressive Cells** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Prostaglandin 2 (PGE2)/EP2/protein kinase A (PKA) Signaling Pathway** | **CAR-T cells in blood cancer and solid tumors** |
| **Adenosine Mediates Immunosuppression** | **On-target/off-tumor toxicity** |
| **Activates PKA** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Blocks TCR Activation** | **CAR-T cells in blood cancer and solid tumors** |
| **Regulatory Subunit I Anchoring Disruptor (RIAD)** | **On-target/off-tumor toxicity** |
| **Diminishes Negative Effects of PKA on TCR Activation** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Catalase (CAT)** | **CAR-T cells in blood cancer and solid tumors** |
| **Overexpressing CAT** | **On-target/off-tumor toxicity** |
| **Produces More Intracellular CAT** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Reduced Oxidative State** | **CAR-T cells in blood cancer and solid tumors** |
| **Less ROS Accumulation** | **On-target/off-tumor toxicity** |
| **PD-L1** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Programmed Cell Death Ligand 1 (PD-L1)** | **CAR-T cells in blood cancer and solid tumors** |
| **Release of Immune Checkpoint Blockade Antibodies** | **On-target/off-tumor toxicity** |
| **Armored CAR-T Cells** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Anti-PD-L1 Releasing CAR-T Cells** | **CAR-T cells in blood cancer and solid tumors** |
| **Decrease Tumor Growth** | **On-target/off-tumor toxicity** |
| **Five Times** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Humanized Mice Model of Renal Cell Carcinoma** | **CAR-T cells in blood cancer and solid tumors** |
| **Remarkable Immune Checkpoint Blockade** | **On-target/off-tumor toxicity** |
| **Clinical Trials for Different Targets** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Modification of CAR-T Cells** | **CAR-T cells in blood cancer and solid tumors** |
| **Different Means** | **On-target/off-tumor toxicity** |
| **Gene-Editing Tools, Pharmacological Inhibitors, and Others** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Best Way** | **CAR-T cells in blood cancer and solid tumors** |
| **Open New Avenues** | **On-target/off-tumor toxicity** |
| **Achieve Results** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Solid Tumors** | **CAR-T cells in blood cancer and solid tumors** |
| **Hematologic Malignancies** | **On-target/off-tumor toxicity** |
| **Rare, Tumor-Specific Antigens** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Identification and Use of TAAs** | **CAR-T cells in blood cancer and solid tumors** |
| **Take Different Means** | **On-target/off-tumor toxicity** |
| **Gene-Editing Tools, Pharmacological Inhibitors, and Others** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
| **Best Way** | **CAR-T cells in blood cancer and solid tumors** |
| **Open New Avenues** | **On-target/off-tumor toxicity** |
| **Achieve Results** | **Unique, tumor-specific antigens are rare, so the approach depends on the identification and use of TAAs. TAAs are self** |
antigens and can be expressed on normal tissues (CD19 is an example of this), requiring careful selection and de-risking of possible targets. TAAs can also be derived from subtle modifications of self-molecules, and there are potential strategies that can leverage differences in antigen density between tumor cells and normal cells\(^6\). However, heterogeneity can be an issue, as TAAs can be expressed at lower levels or even be missing from subpopulations of tumor cells. Most importantly, tumor cell populations are quite adept at evading immune detection and employ a large array of mechanisms to do so\(^7\). These include the downregulation of the expression of TAAs themselves, production of immunosuppressive molecules and/or recruiting immunosuppressive cells, and a tumor microenvironment metabolically hostile to T cell activation and functionality\(^7\). An ideal tumor antigen would allow tumor cell targeting while restricting this targeting to the tumor cell. A CAR-T cell TAA may also be expressed in healthy tissues, which presents the risk of “on-target/off-tumor” toxicity\(^8\). Thus, most CAR-T-targeted antigens are not tumor ‘specific’ but tumor ‘associated’: even though the antigens are expressed on tumors at high levels, they exist in normal cells as well. As a result, “on-target/off tumor” recognition may result in toxicity to normal tissues\(^9\).

CD19 is a favorable target in this regard, which is why it was chosen in so many early CAR-T trials. CD19 is expressed only on normal and malignant B cells. CD19 is expressed on nearly 100% of newly diagnosed ALL and B cell lymphomas. Off-tumor cytotoxicity results in normal B cell aplasia, which in turn results in hypogammaglobulinemia, the principal long term toxicity of a persistent CD19 CAR-T product like CTL019\(^5,6\). In addition to the favorable target profile of the TAA CD19, there are other positive aspects of B cell malignancies and CD19 as CAR-T targets\(^5,6\). Liquid tumors, such as B cell ALL, provide what may be an optimal environment for CAR-T function, without negative regulatory factors such as high local levels of transforming growth factor-beta and hypoxia, which are usually associated with solid tumor microenvironments\(^6\). The CAR-T cells have immediate access to all or most of the ALL cells after infusion, leading to rapid responses and, possibly, more rapid toxicity. Interestingly, DLBCL can be thought of as an “intermediate” between a liquid tumor (like ALL) and a true solid epithelial cancer, since lymphoma cells are often found organized into nodal type masses. This may account for why CRs occur in ALL by 30 days, while full responses in DLBCL can take three months or longer\(^9,6\). One downside of CD19 is that it can be susceptible to editing or downregulation, which can lead to relapse as a result of CD19 antigen escape\(^9,57\).

Other TAAs can present more significant challenges, especially in the solid tumor setting. In a study conducted by Morgan et al.\(^7\), targeting ERBB2 overexpressing tumors has led to the failure of a patient because of respiratory distress secondary to localization of a large number of CAR-T cells to the lung immediately following infusion and, as a consequence, release of inflammatory cytokines. This was thought to occur as a result of the recognition of low levels of ERBB2 on lung epithelial cells. These and similar results emphasize the importance of antigen selection for overcoming on-target/off-tumor toxicity of CAR-T cells. Considerable effort is being expended currently to de-risk solid tumor TAAs before going into clinical trials, but some interactions and some side effects only become apparent in the clinical setting. Altogether, the intensity of reported events ranges anywhere from manageable lineage depletion to severe toxicity, including fatal outcomes in a small number of patients.

Upon overexpression of targets in tumors, affinity-tuned CARs have shown increased tumor specificity\(^5,74\). Moreover, to raise safety and specificity, various dual targeting strategies have been generated. One such strategy is the modification of T cells with two CARs, where CAR number 1 initiates killing by providing the CD3\(\varepsilon\) signal, and CAR number 2 delivers the co-stimulatory signal\(^75\). When both of the antigens are recognized by the CARs, activation of the CAR-T cell is also achieved. Furthermore, inhibitory CARs recognize antigens expressed on non-tumor tissues, and CTLA-4 or PD-1 are able to harness signals exerted by natural T cell inhibition. This method, in preclinical mouse models, has shown to protect healthy tissue from damage caused by off-target effects\(^6\).

3.2. Tumor heterogeneity

Antigen heterogeneity is a significant limitation for all proposed tumor-associated antigens in solid tumors. Heterogeneity is variability in the expression of the antigen on the cells within a given tumor\(^77\). Some cells can have low expression of the TAA, while some cells may be negative for the TAA entirely. Because of this, as a first step in developing a solid tumor, CAR-T is to identify an appropriate and safe, solid TAA, but the second step

| Disease | Antigen | Phase | Clinicaltrials.gov identifier |
|---------|---------|-------|-----------------------------|
| Neuroblastoma, ganglieneuroblastoma | CD171 | I | NCT02311621 |
| Adenocarcinoma | CEA | I | NCT0004178 |
| Colorectal carcinoma | CEA | I | NCT00673322 |
| Breast cancer | CEA | I | NCT00673829 |
| Solid tumor | CEA | I | NCT01212887 |
| Liver metastases | CEA | I | NCT01373047 |
| CEA \(^a\) solid tumors | CEA | I | NCT02349724 |
| Glioblastoma | EGFRvIII | II | NCT02209376 |
| Advanced glioma | EGFR | I | NCT02331693 |
| Ovarian cancer | FR | II | NCT00019136 |
| Neuroblastoma | GD2 | I | NCT01822652 |
| Neuroblastoma | GD2 | I | NCT01460901 |
| Neuroblastoma | GD2 | I | NCT00085930 |
| Neuroblastoma | GD2 | I | NCT02439788 |
| Non-neuroblastoma, GD2 \(^a\) solid tumors | GD2 | I | NCT01207963 |
| Hepatocellular carcinoma | GPC3 | I | NCT02395250 |
| Lung malignancy | HER2 | I | NCT00889954 |
| Metastasized HER2 \(^a\) cancer | HER2 | I | NCT00924287 |
| Brain and CNS tumors | IL-13 zetakine | I | NCT00730613 |
| Gliona, neoplasm | IL13Ra2 | I | NCT02208362 |
| Pancreatic cancer | Mesothelin | I | NCT02465983 |
| Ovarian cancer | Mesothelin | I | NCT01259716 |
| Mesothelioma | | | |
| Prostate cancer | PSA | I | NCT00664196 |
| Head and neck cancer | ErbB | I | NCT01813232 |
| Glioblastoma | EGFRvIII | I/II | NCT01454596 |
| EGFR positive advanced solid tumors | EGFR | I/II | NCT01869166 |
| Solid tumors | HER2 | I/II | NCT01935843 |
may be to deal with this issue of antigen heterogeneity. For example, although mesothelin is expressed on >90% of malignant epithelial mesothelioma tumor cells, it is also expressed on lower percentages of tumor cells in lung, ovarian, and breast cancer. Some CARs can bind to and be activated by antigens that are expressed at very low levels. This is one way of dealing with heterogeneity, but also increases the risk of “on-target/off-tumor” toxicity. Furthermore, most tumor cells escape host immunity by the elimination of immunogenic epitopes. Hence, for solid tumor treatment, identifying immunogenic and specific tumor antigens could be necessary. The ability of CAR-T cells to trigger antigen spreading and/or induce indirect tumor killing is a key question highly relevant to the heterogeneity problem left unanswered.

Several surface antigens are variably expressed by tumor cells, so TAA expression levels can be correlated with a failure of achieving durable responses. Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic kinase activity that belongs to the oncogene family ErbB and is expressed in normal and tumor cells. In the clinical setting, EGFR upregulation is associated with poor prognosis. EGFRvIII is specifically expressed on malignant tumor cells and contains a deletion of the extracellular amino acids 6–273, which leads to constitutive tyrosine kinase activity, eventually promoting tumor metastasis. EGFRvIII-CAR-T cells have the ability to kill EGFRvIII+ tumor cells and also produce effector cytokines, such as interferon-γ. EGFRvIII-CAR-T cells were shown to eliminate glioma cells. Sampson et al. showed that following CAR-T cell therapy directed against EGFRvIII in syngeneic mice after the treatment of brain tumors, the cured mice were resistant to the re-introduction of EGFRvIII-negative tumors which represents the generation of host immunity against additional tumor antigens. In a clinical study of anti-EGFRvIII CAR-T cell therapy for glioblastoma, O’Rourke et al. noted a wide regional variation of EGFRvIII expression in tumor samples after CAR-T cell therapy. Most patients had a loss or decreased expression of EGFRvIII in tumors despite no change in the degree of EGFR amplification or other tumor mutations. The study poses the question of whether targeting EGFRvIII alone can provide durable clinical benefits or whether antigen escape will negate the clinical impact. This may or may not be the case; therefore, the enrollment criteria for CAR-T cell therapy trials need to include prescreening for the intensity and percentage of target antigen expression on tumor cells by immunohistochemistry and/or immunofluorescent techniques. However, these criteria are hard to define prospectively and may result in the need for a companion diagnostic, so the argument can be made to allow patients with lower TAA expression to enroll and then assess clinical responses. Moreover, targeting of various tumor antigens concurrently or in combination (above) could result in a better killing effect and potentially blunt the appearance of target antigen-negative tumor variants.

At this point, at least 30 solid tumor antigens have been evaluated; these include developmental or oncofetal antigens, neoantigens (for example, mutated sequences), endogenous tumor-specific antigens, and tumor-selective antigens (for example, the low-level basal expression on normal cells, but the enriched expression on neoplastic cells). Many of the tumor-associated antigens, for instance, EGFR/EGFRvIII, HER2, mesothelin, IL-13Ra2, Carcinoembryonic antigen (CEA), CD171, and GD2 identified are shown to be highly expressed by solid tumors, thus further allowing for the use of CARs targeting multiple antigens as combination therapies. Antigens resulting from somatic mutations on tumor cells are neoantigens, which can be unique for each patient and serve as tumor-specific antigens instead of TAA. Since their expression is restricted to tumor cells, they are highlighted as an ideal target for CAR-T cell therapy, further minimizing the risk of destroying healthy tissue. Researchers may design CARs targeting abnormal tumor-specific oncogenic mutations or modified tumor-associated antigens. For instance, a study introduced a new CAR unusually targeting glycosylated tumor-associated MUC1 as combination therapies (Table 3). Antigens recognized by the cytotoxicity against normal human primary cells. Similar to this research was a study in ovarian carcinomas reporting that CAR-T cells target MUC16, routinely overexpressed in these types of cancer. CEA is a 180-kD cell surface glycoprotein expressed during developmental growth; however, it is restricted in transformed cells and normal adult tissues. Evidence of tumor eradication in mice has been reported by CEA-CAR-T cells. Preclinical studies demonstrate that anti-CEA CAR-T cells can effectively target CEA expressed in colorectal adenocarcinoma and pancreatic tumors. Another promising target for brain malignancy is the IL-13 receptor α2 (IL-13Ra2), which binds IL-13 with high affinity and modulates its response. Mirzai et al. and other researchers have developed ligand-based CARs for the preferential recognition of IL-13Ra2 over the more ubiquitously expressed IL13Rα1, through the use of membrane-bound IL-13 muteins.

| Cancer                  | Antigen                                |
|-------------------------|----------------------------------------|
| Ovarian cancer          | B7H6, natural killer group 2 member D  |
|                         | (NKG2D), human epidermal growth factor  |
|                         | receptor 2 (HER2), alpha folate         |
|                         | receptor (alpha FR), TNF-related        |
|                         | apoptosis-inducing ligand (TRAIL)       |
|                         | receptor 1 (TRAIL-receptor 1), adhesion |
|                         | molecule L1-CAM (L1-CAM) (CD171)        |
| Glioblastoma            | Interleukin-13Ra2 (IL13Ra2), AC133,    |
|                         | type III variant of the epidermal growth|
|                         | factor (EGFR), erythropoietin           |
|                         | producing hepatocellular A2 (EphA2)     |
| Prostate cancer         | Prostate-specific membrane antigen      |
|                         | (PSMA)                                  |
| Pancreatic cancer       | Prostate stem cell antigen (PSCA),      |
|                         | carcinoembryonic antigen (CEA)          |
| Neuroblastoma           | Disialoganglioside 2 (GD2), L1-CAM      |
|                         | (CD171)                                 |
| Breast carcinoma        | MUC1, chondroitin sulfate               |
|                         | proteoglycan-4 (CSPG4)                  |
| Lung cancer             | EphA2                                   |
| Malignant pleural       | Mesothelin                              |
| mesotheliomas           |                                        |
| Colon cancer            | TRAIL-receptor 1                        |
| Hepatocellular carcinoma| Glypican-3 (GPC3)                       |
| Renal cell carcinoma    | Carbonic anhydrase IX (CAIX)            |
3.3. **CAR-T cell trafficking**

There is a specific interconnection between tumors and surrounding cells, characterizing the organization of tumor tissue. This tumor–tissue connection includes the immune system, for example, the lymphoid and myeloid compartments, the extracellular matrix, fibroblasts, vasculature, and signaling molecules. Fibroblasts, blood vessels, and low nutrients conditions (such as low oxygen and low pH) in surrounding tumors make therapeutic delivery extremely difficult.

Another important obstacle in CAR-T cell therapy of solid tumors is the suboptimal trafficking of CAR-T cells to the tumor site. This trafficking is a dynamic process managed by an interconnected network. CAR-T cells require penetration into the tumor tissue in order to kill tumor cells. Endogenous T-cells are usually excluded from the tumor microenvironment; therefore, a lack of penetration of CAR-T cells into the tumor has been seen with many solid tumor CARs.

Local delivery of CAR-T cells into the tumor can enhance their effectivity in therapy; however this is impractical in patients with many metastatic lesions. The successful application of CAR-T cells in hematological malignancies is associated with the fact that effector and tumor cells share hematopoietic origins, therefore, causing a higher tendency for them to migrate to lymph nodes and bone marrow. In contrast, solid tumors secrete factors, including chemokines (such as CXCL12 and CXCL5, growth factors, and cytokines), which prevent effector T cells from infiltrating into the tumors. Hence, whereas CAR-T cells are transferred intravenously to gain access to hematologic malignancies in the periphery, most solid tumors are not as easy to reach.

After infusion, CAR-T cells require migration to the blood circulation, extravasation, and infiltration to the tumor site to initiate their functions. The extravasation of T cells is dependent on the transendothelial migration of leukocytes and chemokines, their interaction with specific adhesion molecules, firm adhesion, mediated capture, and rolling behavior. For effective therapy using CAR-T cells and the enhancement of their migration to tumor sites, various studies have shown the expression of receptors-matched with tumor-secreted chemokines on CAR-T cells. Moon and colleagues revealed that the overexpression of CCR2b in anti-mesothelin CAR-T cells led to a more than 12.5-fold increase in CAR-T cells homing toward mesothelin-malignant pleural mesothelioma in mice, leading to improved anti-tumor effects.

Another study described that the expression of CCR2b on GD2-CAR-T cells resulted in a more than 10-fold increase in CAR-T cells migrating to CCL2 secreting neuroblastoma cells.

Myeloid cells and tumor fibroblasts have the ability to contribute to pro-tumoral fibrotic extracellular matrix development which may result in the interference of the penetration of T-cells. Also, T lymphocytes during extravasation constantly degrade extracellular matrix (ECM) components as well as subendothelial basement membranes. This includes heparan sulfate proteoglycans (HSPGs), which constitute the majority of the extracellular matrix. To facilitate CAR-T infiltration into the tumor stroma, Caruana et al. developed CAR-T cells to overexpress the heparanase enzyme to degrade heparan sulfate proteoglycans (HSPGs). The ECM is an integral component of the stroma, and therefore, CAR-T cells attacking stroma-rich solid tumors must be armed with enzymes to degrade HSPGs in order to infiltrate readily into tumor stroma and exert anti-tumor effects. The authors found that engineered CAR-T cells expressing heparanase promote more efficacious anti-tumor activity. These studies support the concept that arming of CAR-T cells with a chemokine receptor or ECM-degrading enzyme(s) could facilitate infiltration into the tumor stroma and enhance anti-tumor efficacy.

Moreover, methods have been developed in the context of non-CAR-T therapy, which may become beneficial in infiltrating the physical barrier and supplementing CAR-T cell trafficking. In polarized epithelial tumor cells, manipulation of JO-1 transiently separated tight junctions, which caused an increased efficiency in monoclonal antibody (mAb) treatments in xenograft tumor models.

Tumor endothelial cells express a variety of molecules, including tumor necrosis factor (TNF)-related apoptosis-inducing ligands, PD-L1, IL-10, transforming growth factor beta (TGF-β), and indoleamine-pyruvate 2,3-dioxygenase (IDO), which may contribute to immune suppression. Previous studies have highlighted that vascular targeting drugs can decrease endothelial expression of immunosuppressive molecules and can specifically reverse endothelial cell-induced exhaustion and further improve CAR-T cell therapies.

3.4. **CAR-T cell persistence**

The administration of anti-HER2 CAR-T cells to patients with sarcoma (up to 10⁸ cells/m²) has demonstrated no evident toxic effects but limited anti-tumor activity and T cell persistence. To improve the persistence of adoptively transferred CAR-T cells, Pule et al. generated virus-specific CAR-T cells. By conducting a phase I dose-escalation study, the team examined the safety and efficacy of autologous anti-HER2 CAR virus-specific T cells in 17 patients with progressive glioblastoma. Although the CAR-T cells did not expand, the cells were detectable in the peripheral blood for up to 12 months. Of eight patients, one had a partial response and seven had a stable disease. The median overall survival was 11.1 months after CAR-T cell infusion and 24.5 months after diagnosis. The results highlight the need for the improvement in expansion and persistence of CAR-T cells. To boost CAR-T cell survival, various studies have demonstrated that the local production of IL-15, IL-7 and IL-12 could improve CAR-T cell expansion, induce expansion of CAR-T memory stem cells and prolong persistence in vivo by increasing the expression of anti-apoptotic molecules, such as BCL-2. Koneru et al. showed that secretion of IL-12 by CAR-T cells could eradicate human ovarian xenografts. The authors showed that IL-12-secreting CAR-T cells display improved anti-tumor efficacy as described by increased survival, prolonged persistence of T cells, and higher systemic IFN-γ. However, it should be pointed out that the authors have measured the secretion of human IL-12 (P70) in the serum of CAR-T cell-treated SCID-Beige mice (with normal macrophages and dendritic cell populations) with established ovarian tumors. Since SCID-Beige mice have normal macrophages and DCs populations, and these cells are endogenous sources of mouse IL-12 production upon tumor challenge, these mice could, in fact, produce IL-12 after tumor challenge. The total concentration of serum IL-12, therefore, consisted of both endogenous and exogenous IL-12, and it may not solely reflect IL-12 production by IL-12-secreting CAR-T cells.

3.5. **Metabolic and physical barriers**

Nutrient starvation is a second key factor inhibiting the proliferation of T-cells and the production of cytokines, due to glucose limitation, other metabolites and increased levels of lactate.
(leading to acidosis). The deficiency of nutrients, especially amino acids (such as arginine, lysine, and tryptophan) are able to activate the integrated stress response, further regulating T cell activity. Though tryptophan cannot be synthesized, it is essential for many biological functions. Tryptophan metabolism is catalyzed by IDO. Myeloid cells and tumor cells can express IDO in the tumor microenvironment, leading to T cell anergy, death, and also T-reg accumulation. Researchers recently showed that IDO expression could also inhibit CAR-T cells. In particular, Ninomiya et al. demonstrated that CD19 CAR-T cells were not able to manage the improvement of CD19 IDO-expressing tumors. In addition, they showed that cyclophosphamide and fludarabine administration improved CAR-T cell effectiveness by decreasing IDO expression. For malignancies resistant to immunotherapy and chemotherapy, the combination of IDO inhibitors and CAR-T cells may represent a valuable option.

3.6. Tumor-derived soluble factors and cytokines

In sera, published work has shown that the tissue extracts and ascites fluids from cancer patients contain soluble immunosuppressive factors. PKA is the downstream effector of two immunosuppressive factors: 1, PGE2 and 2, adenosine.

Many studies have reported the role of PGE2 and adenosine molecules as key inhibitors of both the proliferation and activity of T cells. Furthermore, various studies have reported the subversion of CD8 differentiation through PGE as well as CD4 suppression. Both these molecules elicit immunosuppressive effects through the signaling of G-coupled receptors, further activating protein kinase A. TGF-β is a significant cytokine that negatively regulates the immune response. Cytokines involved in inflammatory reactions in a tumor can act as a double-edged sword, either inhibiting or bolstering the anti-tumor reaction. The ability of TGF-β to enhance matrix production, promotes epithelial-to-mesenchymal transition, manipulate immune responses towards a Th2 phenotype, and finally promote metastasis, has direct negative effects on the functions of effector T-cells.

The tumor microenvironment can either suppress or overall inactivate CAR-T cells, even upon successful trafficking to tumor sites. So, in CAR-T cell studies, strategies named TRUCK (T cells Redirected for Universal Cytokine Killing) are being developed.

The aim is for CAR-T cells to gain the capability of remodeling tumor microenvironment’s suppressive function by secreting anti-cancer cytokines. Recently, several cytokines, including interleukin (IL)-12, IL-18, and TNFRSF14 have been utilized in TRUCK designs. IL-12 is an inflammatory cytokine able to induce a Th1 (CD4⁺) response, improve T-cell activation, be cytotoxic to T cell (CD8⁺) clonal expansion, and has effector function. The ability of TRUCKs to change the tumor microenvironment and their utilization to deliver a range of cytokines warrants further exploration.

3.7. Immunosuppressive immune cells

Regulatory T cells (T-regs) are T cells that suppress immune activity and regulate immune responses, including type 1 T-regs and CD4⁺CD25⁺ T-regs, and its absence results in lethal autoimmunity. FOXP3, a regulator of CD4⁺CD25⁺ T-reg transcription factor, is highly expressed on T-regs, while TGF-β is essential for its function. Generally, T-regs are highly expressed at tumor sites and in inflammation, where an immune reaction is regulated. Furthermore, T-regs can produce many immunomodulatory cytokines such as TGF-β and IL-10 in order to suppress the activity of T cells. CD4⁺/FOXP3⁺ T-regs are known suppressors of T cell activity functioning through contact-dependent mechanisms or IL-10 and TGF-β secretion. Since selectively depleting T-regs are difficult, studying the effects of them on therapy by CAR-T cells has been difficult. However, some studies have been performed using either the adoptive transfer of T-regs genetically or depletion approaches with CAR-T cells. Tumor regression in the tumor microenvironment was accompanied by a decrease of myeloid-derived suppressor cells. However, the role of MDSCs is in the modulation and mechanism of increased anti-tumor activity remains to be seen.

Altogether, it seems that modification of CAR-T cells by different means such as using gene-editing tools, pharmacological inhibitors and concomitant targeting of immunosuppressive mechanisms will open new avenues for cancer immunotherapy particularly in the treatment of solid tumors.

4. Production of CAR-T cells

The protocol to generate CAR-T cells follows specific quality controlled steps, which must be performed with precision and under Good Manufacturing Practice (GMP) conditions. The production of CAR-T cells is a multi-step process, including leukapheresis to collect cells from the patient, T cell stimulation, transfection or transduction, expansion, and extensive release testing. After successful manufacturing, the patient undergoes lymphodepleting chemotherapy to maximize cell engraftment and expansion, followed by infusion. Initially, leukapheresis removes blood from the patient while separating the leukocytes, which include T cells. Separation of T cells, where needed, can be performed by bead selection or size/density centrifugation approaches (Fig. 2). The next phase is the activation of T cells, harnessing signals which mimic T cell activation by antigen-presenting cells (APCs). T cell activation consists of two signals, signal 1 (the primary specific activation signal delivered by the T cell receptor) and signal 2 (co-stimulatory signals such as those mediated by CD28, 4-IBB, or OX-40). Initially, ex vivo culture systems involved anti-CD3 antibody and IL-2. More recently, the APC role can be more completely replaced by substrates or beads coated with anti-CD3 and anti-CD28 monoclonal antibodies, which provide both activation signals and better preserve the proliferative phenotype required for in vivo CAR-T function. Another T cell activation approach is the use of artificial antigen-presenting cells (AAPCs). The AAPCs or beads are removed from the T cells at the end of the culture through magnetic separation. The selection and generation of a favorable manufacturing procedure for (GMP)-grade AAPC lines, due to its complexity, requires additional resources. Currently, CAR-T manufacturing introduces the CAR gene using viral gene transfer systems. In a separate phase of manufacturing, the viral vector encoding the CAR is incubated with T cells. Eventually, the vector is diluted out of the culture and/or washed away through the change of medium, and the vector is not infused into the patient. For clinical applications, the vectors routinely used for stable gene expression are γ-retroviral vectors and lentiviral vectors. Lentiviral vectors compared to retroviruses are used with more reliability and also transduce T cells more effectively; however, the production of GMP lentiviral vectors is expensive, with limited GMP manufacturing capacity currently available worldwide. Various non-viral approaches, such as the Sleeping Beauty
transposon/transposase system, or mRNA transfection methods, can also be used\(^{149,150}\). While the Sleeping Beauty transposon system has been used in early phase clinical trials and is cost-effective, their efficiency remains an issue. Transient mRNA transfection is used for CAR-T cell generation; however, several rounds of CAR-T cell infusion is required for this method to be executed properly. During culture, the goal is to activate and expand the gene-modified cells. In GMP manufacturing, culture mixing is required to grow cells in large numbers, and optimal gas exchange is a must. For this, bioreactor culture systems have been designed, such as the GE WA VE, which is widely used for expansion. This bioreactor uses a rocking platform further to expand the CD19-targeted CAR-T cells\(^{151}\). For the expansion of cells from low seeding densities, a relatively new platform is used called G-Rex. The G-Rex is basically a cell culture flask containing a gas-permeable membrane. The advantages of G-Rex include the one time upfront feeding regimen, allowing for the reduction of volume at harvest time, its low seeding density, and the ease of using an incubator for cell growth\(^{152}\). Newer and more modular technologies (such as the CliniMACS Prodigy) afford a single device used for CAR-T cell manufacturing that accomplishes all phases altogether\(^{153}\). Owing to the multifaceted nature of CAR-T cell products, a cautiously planned list of in-process and release tests is essential to afford sufficient evidence of identity, safety, purity, and potency. The identity of CAR-T cell products is usually characterized by CAR surface expression\(^{143,154}\). Safety requires a lack of unsafe contaminations, such as endotoxin, mycoplasma, replication-competent retrovirus or lentivirus (RCR or RCL), and prevention of genotoxicity by properly limiting the level of transgene integration. The purity of the product depends, in part, on specified levels of CD3\(^{+}\) and CAR\(^{+}\) T cells. The impurities incorporated by initial patient material and ancillary elements, such as undesired cell types, tumor burden, and residual beads, have to be below certain specific levels approved by the U.S. Food and Drug Administration (FDA)\(^{155}\). Up to now, the potency of CAR-T cells is frequently determined by \textit{in vitro} cytotoxic T lymphocyte assays or interferon-\(\gamma\) production. Based on the nature of the specific product, further testing may be essential. Setting up of a complete testing panel with the guidance of the FDA in the early development phase is necessary for the final commercialization of the product. Table \ref{table:release-tests}\(^{141,149,151}\) recaps selected CAR-T cell release tests using different genetic modification methods. After the cells reach the numbers required for clinical uses, they are collected, may be cryopreserved, and transferred back to the clinical center for patient infusion.

5. **TCR-T therapy**

In the same way as CAR-T cell therapy, T-cell receptor-engineered T cell (TCR-T) is a type of adoptive cell therapy that uses genetically altered T cells to treat tumors\(^{156,157}\). In the case of TCR-T, T cells are adapted to express a TCR capable of interacting with a cancer-specific peptide-MHC (P-MHC). This peptide can be a tumor-associated antigen (TAA) overexpressed by the tumor or a neo-antigen, which differs from a wild-type antigen through mutations that cannot be recognized through self-tolerance mechanisms\(^{158,159}\). TCRs must be compatible with human leukocyte antigen (HLA), recognizing P-MHCs, and promoting cancer cell death\(^{160}\). While CAR-T cells act by binding their receptor to the surface antigens of cancer cells, comprising only about 28% of the antigens available, TCR-T can bind to peptides originally secreted or located inside the cell, expanding the range of tumor targets. The selection of a specific TCR can be performed by different approaches, usually involving single-cell sequencing or clonal T cell analysis as the final steps\(^{161,163}\).

Clinical trials indicate that TCR-T cells are more effective than CAR-T cell therapy in solid tumors\(^{157,160,164}\). However, some disadvantages are the limited number of tumor-specific TCRs, the possibility of TCR chain cross pairing between the introduced and endogenous TCR chains, and the need to match the patient’s HLA\(^{157,159}\). Although CAR-T cells have a limited number of antigens that can be targeted, they do not have this type of limitation and can be used in all patients. In addition, the downregulation or loss of HLA can be a strategy of immune evasion by malignant cells that can be a limitation of the therapy with TCR-T, but not of CAR-T cells\(^{157}\). As an advantage, it appears that TCR-T cells mediate the release of lower levels of cytokines, decreasing the consequent risk to developing cytokine release syndrome when compared to CAR-T cells\(^{165,166}\). Also, CARs do not have a self-regulatory mechanism, while engineered TCRs and native
T Cells, are subjected to the same mechanisms of activation and auto regulation\textsuperscript{157}. New exciting efforts have been applied to produce non-MHC restricted TCR-T cells. The monomorphic MHC class I-related protein (MR1)-restricted TCR that recognizes cancer cells of different origins, being inert to non-tumor cells\textsuperscript{167} and the anti-cancer $\gamma$δ TCRs that recognizes metabolites over-produced by cancer cells\textsuperscript{168}, are attractive candidates to be used as “off-the-shelf” TCRs.

In a systematic review, Zhang and Wang\textsuperscript{164} showed that there is a general trend of increasing in the number of clinical trials using TCR-T cells from 2004 to 2018. It is also clear from the review that TCR-T cell therapy is a therapeutic tool relatively new, compared to CAR-T cell\textsuperscript{160} and that there is still a long way to the clinical application of this therapy. The vast majority (84\%) of the clinical trials examined by Zhang and Wang\textsuperscript{164} were performed on solid tumors, possibly because CAR-T has already proven its efficiency in the treatment of hematological malignancies, while, as evidenced by several studies, its effects on solid tumors have not been so successful.

6. Conclusions and future directions

Cancer immunotherapy has been evolving on several fronts, most heading in the direction of immune checkpoint blockade and CAR T-cell therapy. CAR-T was the first genetic therapy to be approved by the FDA, and has an undeniable potency, especially for the treatment of hematological tumors. Nevertheless, multiple factors impact the efficacy of CAR-T therapy, including the type of CAR structure, the quality of T cells infused and host-specific factors, such as tumor heterogeneity and the tumor microenvironment.

The variable genotypic and phenotypic profiles presented by malignant cells make their complete eradication a real challenge. For a therapeutic strategy to be promising, in addition to its high potency and low toxicity, it must act concomitantly on different targets or regulating different mechanisms that favor tumor regression. Therefore, the use of multi-specific CAR-T cells and armored CAR-T cells, especially the ones able to induce on-target immunomodulation, have more chances to induce robust clinical outcomes. The importance of this approach can be seen by the increasing number clinical protocols available based on CAR-T cells that can release immune checkpoint blockade antibodies. The release of bispecific T-cell engager (BiTE) by CAR-T cells is another attractive alternative to improve CAR-T cells function with low toxicity\textsuperscript{169}. BiTE is a bispecific protein that has two linked scFvs, one targeting a cell-surface molecule on T cells (for example, CD3ε) and the other targeting a tumor antigen on malignant cells, resulting in T-cell responses and killing of tumor cells\textsuperscript{170}. There are some technologies, such as XTEN, where bispecific T-cell engagers are bounded to a “polyethylene glycol-like” tail, which can be cleaved by proteases present only in the inflammatory tumor milieu, allowing the local delivery of BiTEs with lower toxicity\textsuperscript{171}. A possible release of bifunctional checkpoint-inhibitory T cell engagers (CiTEs) by CAR-T cells is also an exciting alternative to improve the functionality of CAR-T cells\textsuperscript{172}. We can also have an even more personalized therapy since there are some clinical trials where the immunophenotyping of the patient’s tumor defines the type of CAR-T cells that will be produced (NCT03423992).

Patients treated with CAR-T cells can have some serious adverse effects, such as tumor lysis syndrome and cytokines release syndrome (CRS) that, despite manageable, can become severe complications if not appropriately handled. On-target off-tumor toxicity is also a concern, and some current approaches allow specific CAR-T cell ablation, if necessary. Among them, we can cite the insertion of a suicide gene into the CAR, for example, the inducible caspase-9, which can be activated by a small drug called rimiducid (AP1903), leading to apoptosis of CAR-T cells\textsuperscript{173} or the co-expression of CD20 or EGFRt by the CAR, sensitizing it to the treatment with rituximab or cetuximab.
Some designed CAR-T cells can be inhibited when they bind to a specific antigen expressed only by healthy cells, despite the simultaneous binding with their TAA, blocking off-target effects. A decrease in the dose used in CAR-T studies is also a possible strategy to minimize off-target effects, and a mathematical model has shown that using one-tenth and even one percent of the current CAR-T doses used in pre-clinical trials can lead to similar results. Therefore, lower CAR-T doses must be tested in pre-clinical and clinical trials.

The resistance to CAR-T cell therapies is a significant limitation, commonly caused by loss or downregulation of TAA expression. A recent paper has shown that CARs can induce reversible antigen loss through a process called trogocytosis. In this process, the TAA is transferred to T cells, impairing target density on tumor cells, and promoting T cell killing and exhaustion. The reversion of the antigen loss processes must be explored to counteract the resistance to CAR-T cell therapies. Besides, circulating tumor cells can be collected together with lymphocytes by apheresis, and the CAR can be transduced into these tumor cells, binding in cis to the target antigen expressed by the same cell, leading to tumor cell escape. This effect was seen in a patient that relapsed nine months after CD19-targeted CAR-T cell therapy.

The treatment of solid tumors with CAR-T cells is a challenge due to the immunosuppressive microenvironment of these tumors, and the difficult CAR-T trafficking and persistence. CAR-T cells have been adapted to express chemokines and cytokines, such as CCR2 or CCR2, alone, CCL19 associated with IL-7, improving transendothelial migration and intratumoral trafficking, with prolonged survival and complete tumor regression in different solid tumors. Besides, some enzymes that can, for example, degrade the extracellular matrix compounds, such as heparanase, were also coupled in the second cassette of CAR constructs, improving T cell infiltration and anti-tumor activity; however, this approach raises some concerns due to its intrinsic nonspecificity.

The costs and time involved in autologous CAR-T cell manufacturing is another big issue, and the use of allogeneic universal CAR-T cells made from healthy donors could make these therapies more accessible to the majority of the population. This option could also be useful in patients with lymphopenia or dysfunctional T cells. The use of CRISPR or other gene-editing nucleases to knock out HLA, as well as the endogenous TCR, could eliminate rejection, graft-versus-host disease, and cross-reactivity, dramatically reducing costs and time with a functional allogeneic universal CAR T cell therapy.

Most of the drawbacks of CAR-T therapy, including their safety and efficacy, can be improved by using gene-editing technologies and synthetic biology, which also implicate in risks. The safety of the viral vector used for CAR-T cells must be considered, since the integration of viral vectors can induce insertional mutagenesis, disrupting tumor-suppressor genes or activating proto-oncogenes, with ability to transform healthy CAR-T cells in malignant clones. The use of non-viral vectors, such as Sleeping Beauty transposons—especially the cassettes vectorized as minicircles associated with mRNA transposase—can be an alternative to improve both safety and costs.

Moreover, the growing amount of information resulting from the several clinical trials performed with CAR-T cells can also address several clinical trials performed with CAR-T cells can also address important questions regarding the safety and efficacy of genic therapy, setting up new directions and opportunities for this field. There is a very significant investment into CAR-T approaches by large pharma, biotech startups, and many academic medical centers, much of which has been devoted to solving the current limitations of CAR-T cell therapies. As rapidly as this field is moving, the one prediction we can make for certain is that 5–10 years from now, the field will look entirely different. We are just at the beginning.

7. Practice points

- In the clinical setting, CAR-T cells have shown particular effectiveness in the treatment of B cell malignancies, and some clinical trials using anti-B cell maturation antigen CAR-T cells have shown remarkable activity for the treatment of multiple myeloma.
- The expression rates of the TAA target for CAR-T cell therapy must be confirmed since they determine the therapeutic efficacy.
- Lymphodepletion ameliorates CAR-T cell performance in most cases.
- Second-generation CAR-T cells are the best studied in clinical trials until now, and the 4-1BB co-stimulatory domain is slightly superior for long-term results compared to CD28. However, third-generation CARs combining both co-stimulatory domains are superior in most pre-clinical studies.
- Armed CAR-T cells able to release immune checkpoint blockade antibodies, BiTEs, CiTEs, enzymes, cytokines or chemokines have been promising in pre-clinical and clinical trials, improving the therapeutic efficacy of CAR-T cells against solid tumors.
- The choice of non-viral vectors can be a safer and cheaper alternative for CAR-T cell production.
- CAR-T cells are beyond cancer, with additional power to treat autoimmune diseases and some viral infections, such as HIV, hepatitis B, hepatitis C, cytomegalovirus as well as some opportunistic fungus infections. Anti-HIV CAR-T cell therapy is already on clinical trials.
- The use of all-in-one closed systems, such as ClinMACS Prodigy or similar for CAR-T cell production in clinical scale may improve the feasibility of this therapeutic approach.

8. Research agenda

- Limited clinical efficacy has been seen for the treatment of solid tumors with CAR-T cells, and the research in this field must be continually refined and improved.
- The loss or downregulation of the TAA on tumor cells remains an essential hurdle to the sustained effects of CAR-T-based therapies and strategies to block trogocytosis, and other mechanisms related to antigen loss or downregulation might increase the durability of CAR-T therapies, with consequent better outcomes.
- The search for more specific TAAs must go on.
- Better manufacturing processes to reduce time and costs for CAR-T cell production are necessary.

Author contributions

Stephan A. Grupp, Ghanbar Mahmoodi Chalbatani and Hassan Dana designed the study. Hassan Dana, Ghanbar Mahmoodi Chalbatani, Seyed Amir Jalali and Eloah Rabello Suarez wrote the manuscript. Hamid Reza Mirzaei and Catarina Raposo helped...
CAR-T cells in blood cancer and solid tumors

supervise the project. Stephan A. Grupp and Thomas J. Webster approved final version.

Conflicts of interest

Stephan A. Grupp receives study support from Novartis, Kite, Servier, and Vertex. He consults for Novartis, Roche, GSK, Humanigen, CBMG, and Janssen/JNJ. He is on study steering committees or scientific advisory boards for Novartis, Allogene, Jazz, Adaptimmune, TCR2, Collectis, Juno, and Vertex/CRISPR. He has a patent (Toxicity management for anti-tumor activity of CARs, WO 2014011984 A1) that is managed according to the University of Pennsylvania patent policy. The other authors declare no conflicts of interests in this work.

References

1. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117:1137–46.
2. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509–18.
3. Gun SY, Lee SWL, Sieow JL, Wong SC. Targeting immune cells for cancer therapy. Redox Biol 2019;25:101174.
4. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714–27.
5. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Antitumor response by genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther 2019;4:35.
6. DiNoia AM, Maude SL. Chimeric antigen receptor T-cell therapy clinical trials in pediatric and young adult B-ALL. Hematologia 2019;3:e279.
7. Li D, Li X, Zhou WL, Huang Y, Liang X, Jiang L, et al. Genetically engineered T cells for cancer immunotherapy. Sci Transl Med 2019;117:1178–73.
8. Liu D, Li X, Zhou WL, Huang Y, Liang X, Jiang L, et al. Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther 2019;4:35.
9. Porter DL, Levine BL, Kalos M, Bagg A, June CH, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725–33.
10. Baker SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 2017;377:2545–54.
11. Wang K, Liu Y, Li J, Wang B, Bishop R, White C, et al. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies. Cytotherapy 2019;21:1081–93.
12. Harrison RP, Zylberberg E, Ellison S, Levine BL, et al. Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. Cytotherapy 2019;21:224–33.
13. Whilding LM, Maher J. CAR T-cell immunotherapy: the path from the by-road to the freeway?. Mol Oncol 2015;9:1994–2018.
14. Liu D. CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J Hematol Oncol 2019;12:113.
15. Galluzzi L, Vacchelli E, Pedro JMBS, Baqué A, Senovilla L, Baracco EE, et al. Classification of current anticancer immunotherapies. Oncotarget 2014;5:12472–508.
16. Anfossi N, André P, Guiu S, Fark CS, Roetynck S, Stewart CA, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006;25:331–42.
17. Sha HH, Wang DD, Yan DL, Hu Y, Yang SJ, Liu SW, et al. Chimeric antigen receptor T-cell therapy for tumour immunotherapy. Biosci Rep 2017;37:BSR20160335.
18. Hu W, Wang G, Huang D, Sui M, Yibing X, et al. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol 2019;10:1205.
CAR-T cells in blood cancer and solid tumors

97. Campos B, Zeng L, Daotrong PH, Eckstein V, Unterberg A, Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Lorimer IA. Mutant epidermal growth factor receptors as targets for adaptive resistance in patients with recurrent glioblastoma. *Hum Gene Ther* 2013;24:1822–38.

98. Meyer D, Knobloch P, Desai A, Melenhorst JJ, Mansfield K, Lorimer IA. Expression and regulation of AC133 and CD133 in glioblastoma. *BioDrugs* 2014;28:335–46.

99. Kakarla S, Chow KKH, Mata M, Shaffer DR, Song XT, Wu MF, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. *Mol Ther* 2013;21:1611–20.

100. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. *Nat Med* 2007;13:1440–9.

101. Abate-Daga D, Lagissetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. *Hum Gene Ther* 2014;25:1003–12.

102. Chmielewski M, Rapp J, Hornbach AA, Abken H. T cells redirected by a CD3zeta chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term. *Gene Ther* 2013;20:177–86.

103. Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. *J Immunol* 2008;180:4901–9.

104. Goldes J, Savoldo B, Hoyos V, Caruana I, Zhang M, Yvon E, et al. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. *Clin Canc Res* 2014;20:962–71.

105. Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. *Mol Ther* 2013;21:629–37.

106. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. *Cancer Immunol Immunother* 2014;63:112–20.

107. Kretz AL, Tauzold A, Hillenbrand A, Knipschild U, Hennebruns D, Karstedt SV, et al. TRAILblazing strategies for cancer treatment. *Cancers (Basel)* 2019;11:456.

108. Di S, Li Z. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects. *Sci China Life Sci* 2016;59:360–9.

109. Lamers CH, Sleijfer S, Steenbergen SV, Elzakker PV, Krimpen BV, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. *Mol Ther* 2013;21:904–12.

110. Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. *Nat Med* 2016;22:26–36.

111. Maher J, Wilkie S, Davies DM, Arif S, Picco G, Julien S, et al. Targeting of tumor-associated glycoform of MUC1 with CAR T cells. *Immunity* 2016;45:945–6.

112. Posey Jr AD, Clausen H, June CH. Distinguishing truncated and normal MUC1 glycoform targeting from Tn-MUC1-specific CAR T cells: specificity is the key to safety. *Immunity* 2016;45:947–8.

113. Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, Levine DA, et al. Recognition of glioma stem cells by genetically engineered T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. *Hum Gene Ther* 2012;23:1043–53.

114. Suryadevara CM, Sanchez-Perez L, Yang S, Leon GD, et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. *PLoS One* 2014;9:e94281.

115. Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Ren PP, Li M, Li TF, Han SY, et al. EGFRvIII-specific chimeric antigen receptor T cells: current status and future prospects. *Hum Gene Ther* 2014;25:1003–12.

116. Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, Levine DA, et al. EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Clin Canc Res* 2014;20:972–84.

117. O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Lorimer IA. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Sci Transl Med* 2017;9:eaaa6984.

118. Lorimer IA. Mutant epidermal growth factor receptors as targets for cancer therapy. *Curr Cancer Drug Targets* 2002;2:91–102.

119. Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. *Clin Canc Res* 2014;20:972–84.

120. Chen X, Lin S, Wang Y, Liu L, Chen J, et al. EGFRvIII-directed CAR T cells therapeutic efficacy in glioblastoma mouse model. *J Exp Clin Cancer Res* 2013;32:151.
117. Trédan O, Galmarini CM, Patel K, Tannock, et al. Drug resistance and the solid tumor microenvironment. *J Natl Cancer Inst* 2007;99:1441–54.

118. Yong CSM, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH. CAR T-cell therapy of solid tumors. *Immunol Cell Biol* 2017;95:356–63.

119. Adusumilli PS, Cherkaissy L, Villena-Vargas J, Colocos C, Servais E, Plotkin J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. *Sci Transl Med* 2014;6:261ra151.

120. Enblad G, Karlsson H, Loskog AS. CAR T-cell therapy: the role of physical barriers and immunosuppression in lymphoma. *Hum Gene Ther* 2015;26:498–505.

121. Ramachandran M, Dimberg A, Essand M. The cancer-immunity cycle as rational design for synthetic cancer drugs: novel DC vaccines and CAR T-cells. *Semin Canc Biol* 2017;45:23–35.

122. Vestweber D. How leukocytes cross the vascular endothelium. *Nat Rev Immunol* 2015;15:692–704.

123. Moon EK, Carpenito C, Sun J, Wang LCS, Kapoor V, Predina J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication byargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. *Clin Canc Res* 2011;17:4719–30.

124. Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. *J Immunother* 2010;33:780–8.

125. Edsparr K, Basse PH, Goldfarb RH, Albertsson P. Matrix metalloproteinases in cytotoxic lymphocytes impact on tumour infiltration and immunomodulation. *Cancer Microenviron* 2011;4:351–60.

126. Stewart MD, Sanderson RD. Heparan sulfate in the nucleus and its control of cellular functions. *Matrix Biol* 2014;35:56–9.

127. Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redireted T lymphocytes. *Nat Med* 2015;21:524–9.

128. Li J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. *J Hematol Oncol* 2018;11:22.

129. Yang S, Ji Y, Gattinoni L, Zhang L, Yu Z, Restifo NP, et al. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. *Cancer Immunol Immunother* 2013;62:722–36.

130. Koneru M, Purnon TJ, Spriggs D, Koneru S, Brenjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. *Onc Immunology* 2015;4:e994446.

131. Mirzaei HR, Hadjati J. Commentary: IL-12-secreting tumor-targeted chimeric antigen receptor T cells: an unaddressed concern on Koneru et al. (2015). *Oncol Rep* 2016;5:1100792.

132. Howie D, Waldmann H, Cobbold S. Nutrient sensing via mTOR in T cells maintains a tolerogenic microenvironment. *Front Immunol* 2014;5:409.

133. Nino-miya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, et al. Tumor indoleamine 2,3-dioxygenase (Ido) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. *Blood* 2015;125:3905–16.

134. Su Y, Huang X, Raskovalova T, Zacharia L, Lokshin A, Jackson E, et al. Cooperation of adenosine and prostaglandin E2 (PG2) in amplification of cAMP-PKA signaling and immunosuppression. *Cancer Immunol Immunother* 2008;57:1611–23.

135. Massague J. TGFbeta in cancer. *Cell* 2008;134:215–30.

136. Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradi- cate established cancers in lymphodepleted hosts. *Canc Res* 2010;70:6725–34.

137. Avanzi MP, Leeuwen DGV, Li X, Cheung K, Park H, Purdon TJ, et al. IL-18 secreting CAR T cells enhance cell persistence, induce prolonged B cell aplasia and eradicate CD19+ tumor cells without need for prior conditioning. *Blood* 2016;128:816.

138. Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. *Exp Opin Biol Ther* 2015;15:1145–54.

139. Haribhai D, Lin W, Edwards B, Ziegelbauer J, Salzmann NH, Carlson MR, et al. A central role for induced regulatory T cells in tolerance induction in experimental colitis. *J Immunol* 2009;182:3461–8.

140. Fontenot JD, Gavin MA, Rudensky AY. Pillars article: Foxp3 progenitors generate CD4+CD25+ regulatory T cells. *J Immunol* 2017;198:986–92.

141. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. *Cell* 2008;133:775–87.

142. Zou W. Regulatory T cells, tumour immunity and immunotherapy. *Nat Rev Immunol* 2006;6:295–307.

143. Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. *Mol Ther Methods Clin Dev* 2017;4:92–101.

144. Scarfo I, Maus MV. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. *J Immunother Cancer* 2017;5:28.

145. Levine BL. Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. *Canc Gene Ther* 2015;22:79–84.

146. Allegra A, Innao V, Gerace D, Vaddinelli D, Musolino C, et al. Adoptive immunotherapy for hematological malignancies: current status and new insights in chimeric antigen receptor T cells. *Blood Cells Mol Dis* 2016;62:49–63.

147. Yun YS, Hargrove ME, Ting CC. In vivo antitumor activity of anti-CD3-induced activated killer cells. *Canc Res* 1989;49:4770–4.

148. East JE, Sun W, Webb TJ. Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells. *J Vis Exp* 2017;120:4333.

149. Singh H, Manuri PR, Olavres S, Dara N, Dawson MJ, Huls H, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping beauty system. *Canc Res* 2008;68:2961–71.

150. Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. *Leuk Res* 2009;33:1255–9.

151. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, et al. Manufacturing validation of biologically active T Cells using the G-Rex Sleeping Beauty system. *Mol Ther Methods Clin Dev* 2014;2:14015.

152. Bajgain P, Mucharla R, Wilson J, skepticism of CAR-T development for autologous use. *J Immunother Cancer* 2009;32:169.

153. Kiser AD, Assennacher M, Schröder B, Meyer M, Orentas R, Bethke U, et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy. *Canc Gene Ther* 2015;22:78–8.

154. Chang ZL, Silver PA, Chen YY. Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors. *J Transl Med* 2015;13:161.

155. Wang X, Rivie`re I. Clinical manufacturing of CAR T cells: founda- tion of a promising therapy. *Mol Ther Oncolytics* 2016;3:16015.

156. Mo Z, Du P, Wang G, Wang Y. The multi-purpose tool of tumor immunotherapy: gene-engineered T cells. J Immunother Cancer 2017;5:22.

157. Getts D, Hofmeister R, Quinta ´ s-Cardama A. Synthetic T cell receptors. *Cancer Res* 2010;70:1611–23.

158. Massague J. TGFbeta in cancer. *Cell* 2008;134:215–30.

159. Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradi- cate established cancers in lymphodepleted hosts. *Canc Res* 2010;70:6725–34.
CAR-T cells in blood cancer and solid tumors

159. Crowther MD, Svane IM, Met Ö. T-cell gene therapy in cancer immunotherapy: why it is no longer just CARs on the road. Cells 2020;9:1588.

160. Garber K. Driving T-cell immunotherapy to solid tumors. Nat Biotechnol 2018;36:215–9.

161. Shitaoka K, Hamana H, Kishi H, Hayakawa Y, Kobayashi E, Sukegawa K, et al. Identification of tumoricidal TCRs from tumor-infiltrating lymphocytes by single-cell analysis. Cancer Immunol Res 2018;6:378–88.

162. Parkhurst M, Gross A, Pasetto A, Prickett T, Crystal JS, Robbins P, et al. Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression. Clin Canc Res 2017;23:2491–505.

163. Janssen A, Hidalgo JV, Beringer DX, Dooremalen SV, Fernando F, Parkhurst M, Gros A, Pasetto A, Prickett T, Crystal JS, Robbins P, et al. Identification of tumoricidal TCRs from tumor-infiltrating lymphocytes by single-cell analysis. Cancer Immunol Res 2018;6:530–43.

164. Zhang J, Wang L. The emerging world of TCR-T cell trials against cancer: a systematic review. Technol Canc Res Treat 2019;18:153303819831068.

165. Xia Y, Yang Z, Horan LH, Zhang P, Liu L, Zimdahl B, et al. A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. Cell Discov 2018;4:62.

166. Harris DT, Hager MV, Smith SN, Cai Q, Stone JD, Kruger P, et al. Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains. J Immunol 2018;200:1088–100.

167. Crowther MD, Dolton G, Legut M, Caillaud ME, Lloyd A, Attaf M, et al. Author correction: genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related antigen MR1. Nat Immunol 2020;21:695.

168. Legut M, Dolton G, Mian AA, Ottmann OG, Sewell AK. CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. Blood 2018;131:311–22.

169. Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol 2019;37:1049–58.

170. Slaney CY, Wang P, Darcy PK, Kershaw MH. CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment. Canc Discov 2018;8:924–34.

171. Podust VN, Balan S, Sim BC, Coyle MP, Ernst U, Peters RT, et al. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers. J Control Release 2016;240:52–66.

172. Goebeler ME, Bargou RC. T cell-engaging therapies—BiTEs and beyond. Nat Rev Clin Oncol 2020;7:418–34.

173. Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety switch” to limit off-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol 2014;5:235.

174. Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Koizlowski M, et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood 2017;129:2395–407.

175. Yu S, Yi Ming, Qin S, Wu K. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Canc 2019;18:125.

176. Levin AG, Kronik N, Shiloach T, Waks T, Eshhar Z, Vainstein V. Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach. Cancer Immunol Immunother 2020;69:1165–75.

177. Hamieh M, Dobrin A, Cabriolu A, Stegen SJC, Giavridis T, Mansilla-Soto J, et al. CAR T cell cytotoxicity with low cytokine release. Cell Discov 2018;4:62.

178. Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemia B cell. Nat Med 2018;24:1499–503.

179. Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 2018;36:346–51.

180. Ren J, Zhao Y. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. Protein Cell 2017;8:634–43.

181. Chichaybarn L, AbdI L, Carneiro M, Peixoto B, Viegas M, Sousa P, et al. CAR T cells generated using Sleeping Beauty transposon vectors and expanded with an EBV-transformed lymphoblastoid cell line display antitumor activity in vitro and in vivo. Hum Gene Ther 2019;30:511–22.

182. Hudecek M, Izsák Z, Johnsen S, Renner M, Thumann G, Ivics Z. Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side. Crit Rev Biochem Mol Biol 2017;52:355–80.

183. Seif M, Einsele H, Loffler J. CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases. Front Immunol 2019;10:2711.

184. Mock U, Nickolay L, Philip B, Cheung GWK, Zhan H, Johnston IC, et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy 2016;18:1002–11.